Clinical Study With Lyrica In Patients Suffering From Epilepsy
Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
- Included all adult patients with partial seizures and without contraindications according to Summary of Product Characteristics (SmPC).
Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration
Adult patiens with partial seizures.
Other inclusion criteria according to Summary of Product Characteristics (SmPC).
Drug: Lyrica (pregabalin)
The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
Intervention: Drug: Lyrica (pregabalin)
* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Actual Enrollment (submitted: May 31, 2011)
Original Estimated Enrollment (submitted: June 17, 2009)
Actual Study Completion Date
Actual Primary Completion Date
June 2010 (Final data collection date for primary outcome measure)
Adult patients with partial seizures.
Contraindications according to Summary of Product Characteristics (SmPC).
Sexes Eligible for Study:
18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Contact information is only displayed when the study is recruiting subjects
Listed Location Countries
Removed Location Countries
Other Study ID Numbers
Has Data Monitoring Committee
U.S. FDA-regulated Product
IPD Sharing Statement
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer CT.gov Call Center
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below: